SCHEMBL23336972

SCHEMBL23336972

CC(C)(C)OC(=O)NCc1ccc(B2OC(C)(C)C(C)(C)O2)cc1C(F)F

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.55
WDR77 Q9BQA1 1/20 0.55
AAK1 Q2M2I8 3/20 0.47
BACE1 P56817 1/20 0.37
BACE2 Q9Y5Z0 1/20 0.37
ROCK1 Q13464 1/20 0.37
HIF1A Q16665 3/20 0.37
DGAT1 O75907 1/20 0.37
KDM4A O75164 1/20 0.35
KCNA5 P22460 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
USP30 Q70CQ3 1/20 0.34
RPS6KA1 Q15418 1/20 0.34
EPAS1 Q99814 1/20 0.33
APLNR P35414 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29418380 1.00 PRMT5 (0.55) PRMT5WDR77AAK1BACE1BACE2
SCHEMBL23336478 0.86 PRMT5 (0.54) PRMT5WDR77AAK1BACE1BACE2
SCHEMBL1290158 0.86 PRMT5 (0.57) PRMT5WDR77AAK1BACE1BACE2
SCHEMBL23303674 0.85 ROCK1 (0.42) PRMT5WDR77AAK1ROCK1HIF1A
SCHEMBL16793978 0.84 PRMT5 (0.58) PRMT5WDR77AAK1BACE1BACE2
SCHEMBL16794372 0.84 PRMT5 (0.56) PRMT5WDR77AAK1BACE1BACE2
SCHEMBL26050668 0.84 PRMT5 (0.52) PRMT5WDR77AAK1BACE1BACE2
SCHEMBL3490524 0.84 PRMT5 (0.57) PRMT5WDR77AAK1BACE1BACE2
SCHEMBL30428827 0.84 PRMT5 (0.57) PRMT5WDR77AAK1BACE1BACE2
SCHEMBL2699076 0.84 PRMT5 (0.57) PRMT5WDR77AAK1BACE1BACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116917279-A BTK inhibitors 渤健马萨诸塞州股份有限公司 2023-10-20 CN disclosed
CN-116635028-A Modulators of c-MYC mRNA translation and their use in the treatment of cancer 艾尼莫生物科技公司 2023-08-22 CN disclosed
WO-2023086521-A1 BTK INHIBITORS BIOGEN MA INC. (US) 2023-05-19 WO disclosed
US-20230025892-A1 CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE BIOGEN MA INC. 2023-01-26 US disclosed
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-11-24 US disclosed
WO-2022150316-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-07-14 WO disclosed
WO-2021087112-A1 CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE BIOGEN MA INC. (US) 2021-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 PRMT5 720/4885WDR77 561/4885AAK1 1898/4885
US-20230025892-A1 CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE ABL1, CDK1, CDK2 PRMT5 1150/4885WDR77 1125/4885AAK1 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.